Details for New Drug Application (NDA): 201688

✉ Email this page to a colleague

NDA 201688 describes TOBI PODHALER, which is a drug marketed by Mylan Speciality Lp and is included in one NDA. It is available from one supplier. There are seven patents protecting this drug. Additional details are available on the TOBI PODHALER profile page.

The generic ingredient in TOBI PODHALER is tobramycin. There are eighteen drug master file entries for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the tobramycin profile page.

Summary for 201688

Tradename:	TOBI PODHALER
Applicant:	Mylan Speciality Lp
Ingredient:	tobramycin
Patents:	7

Pharmacology for NDA: 201688

Medical Subject Heading (MeSH) Categories for 201688

Anti-Bacterial Agents

Suppliers and Packaging for NDA: 201688

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
TOBI PODHALER	tobramycin	POWDER;INHALATION	201688	NDA	Mylan Specialty L.P.	49502-401	49502-401-09	8 CAPSULE in 1 BOX, UNIT-DOSE (49502-401-09)
TOBI PODHALER	tobramycin	POWDER;INHALATION	201688	NDA	Mylan Specialty L.P.	49502-401	49502-401-24	224 PACKAGE in 1 BOX, UNIT-DOSE (49502-401-24) / 56 BLISTER PACK in 1 PACKAGE / 4 CAPSULE in 1 BLISTER PACK

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	POWDER;INHALATION			Strength	28MG
Approval Date:	Mar 22, 2013	TE:		RLD:	Yes
Patent:	10,207,066	Patent Expiration:	Nov 4, 2030	Product Flag?	Y	Substance Flag?		Delist Request?
Patented Use:	TREATMENT OF CYSTIC FIBROSIS PATIENTS WITH PSEUDOMONAS AERUGINOSA
Patent:	11,484,671	Patent Expiration:	Nov 7, 2024	Product Flag?	Y	Substance Flag?		Delist Request?
Patented Use:	TREATMENT OF CYSTIC FIBROSIS PATIENTS WITH PSEUDOMONAS AERUGINOSA
Patent:	7,516,741	Patent Expiration:	Jan 11, 2024	Product Flag?	Y	Substance Flag?		Delist Request?

Expired US Patents for NDA 201688

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Mylan Speciality Lp	TOBI PODHALER	tobramycin	POWDER;INHALATION	201688-001	Mar 22, 2013	RE47526	⤷ Subscribe
Mylan Speciality Lp	TOBI PODHALER	tobramycin	POWDER;INHALATION	201688-001	Mar 22, 2013	7,516,741	⤷ Subscribe
Mylan Speciality Lp	TOBI PODHALER	tobramycin	POWDER;INHALATION	201688-001	Mar 22, 2013	9,421,166	⤷ Subscribe
Mylan Speciality Lp	TOBI PODHALER	tobramycin	POWDER;INHALATION	201688-001	Mar 22, 2013	11,484,671	⤷ Subscribe
Mylan Speciality Lp	TOBI PODHALER	tobramycin	POWDER;INHALATION	201688-001	Mar 22, 2013	8,349,294	⤷ Subscribe
Mylan Speciality Lp	TOBI PODHALER	tobramycin	POWDER;INHALATION	201688-001	Mar 22, 2013	8,069,851	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.